How should I use pemazyre(pemigatinib)?

Pemigatinib is a novel targeted drug used for the treatment of cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR1 gene rearrangement. This article aims to introduce the administration method and dosage of pemigatinib, providing a reference for patients and physicians. Correct administration method and dosage are crucial for the efficacy and safety of the drug; therefore, understanding the appropriate administration method and dosage of pemigatinib is key to ensuring patients achieve the optimal therapeutic effect.

Recommended Dosage of Pemigatinib

1. Recommended Dosage for Patients with Cholangiocarcinoma

The recommended dosage of pemigatinib is 13.5 mg, to be taken orally once daily for 14 consecutive days, followed by a 7-day drug holiday, with a 21-day period as one treatment cycle.

2. Recommended Dosage for Patients with Myeloid/Lymphoid Neoplasms with FGFR1 Gene Rearrangement

The recommended dosage of pemigatinib is 13.5 mg, to be taken orally once daily on a continuous basis.